[Skip to Navigation]
February 1987

Etretinate Therapy for Generalized Pustular Psoriasis in Children

Author Affiliations

From the Division of Dermatology, Department of Pediatrics, Children's Memorial Hospital, Northwestern University Medical School, Chicago (Drs Shelnitz and Esterly), and the Departments of Pediatrics and Dermatology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine (Dr Honig).

Arch Dermatol. 1987;123(2):230-233. doi:10.1001/archderm.1987.01660260100023

• Two children, 19 months of age, were independently treated with a compassionate protocol of etretinate therapy for recalcitrant, debilitating pustular psoriasis. Laboratory test results, roentgenograms of the spine, and bone age were periodically monitored. Over a 3½-year period of intermittent treatment with a maximum dosage of 1.5 mg/kg/d, both children showed remarkable improvement with no apparent drug effect on growth and development. Side effects included xerosis, skin fragility and transient, minimal elevations of aspartate aminotransferase, lactic dehydrogenase, and triglyceride levels. Etretinate therapy may prove to be a viable treatment option for the child with intractable pustular psoriasis that seriously impairs quality of life.

(Arch Dermatol 1987;123:230-233)

Add or change institution